Kimmel Cancer Institute

Alternative to embryonic stem cell research offered

Published in Hospital and Nursing Home Week, April 15th, 2004

Without a doubt, the use of embryonic stem cells raises numerous ethical and scientific questions.

Carlo Croce, MD, director of the Kimmel Cancer Institute and Kimmel Cancer Center at the Thomas Jefferson University, and member of the CorCell Scientific and Medical Advisory Board in Philadelphia, Pennsylvania, suggests there will be a long time before any patients could be treated with cloned embryonic cells.

There are a multitude of problems that must be addressed before this event could take place. For example: during the Korean experiments, the researchers required 242 egg cells which produced 30 blastocysts - a success rate of only 10%. While...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hospital and Nursing Home Week

Source: Hospital and Nursing Home Week (2004-04-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry